Logo image of BNGO

BIONANO GENOMICS INC (BNGO) Stock Fundamental Analysis

NASDAQ:BNGO - US09075F4046 - Common Stock

4 USD
-0.13 (-3.15%)
Last: 8/22/2025, 8:00:02 PM
4.02 USD
+0.02 (+0.5%)
After Hours: 8/22/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, BNGO scores 2 out of 10 in our fundamental rating. BNGO was compared to 54 industry peers in the Life Sciences Tools & Services industry. BNGO has a bad profitability rating. Also its financial health evaluation is rather negative. BNGO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BNGO has reported negative net income.
In the past year BNGO has reported a negative cash flow from operations.
BNGO had negative earnings in each of the past 5 years.
BNGO had a negative operating cash flow in each of the past 5 years.
BNGO Yearly Net Income VS EBIT VS OCF VS FCFBNGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -106.74%, BNGO is not doing good in the industry: 92.59% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -173.69%, BNGO is doing worse than 83.33% of the companies in the same industry.
Industry RankSector Rank
ROA -106.74%
ROE -173.69%
ROIC N/A
ROA(3y)-99.22%
ROA(5y)-76.96%
ROE(3y)-203.87%
ROE(5y)-150.04%
ROIC(3y)N/A
ROIC(5y)N/A
BNGO Yearly ROA, ROE, ROICBNGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

BNGO has a Gross Margin of 1.74%. This is amonst the worse of the industry: BNGO underperforms 90.74% of its industry peers.
In the last couple of years the Gross Margin of BNGO has declined.
BNGO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-61.43%
GM growth 5Y-48.22%
BNGO Yearly Profit, Operating, Gross MarginsBNGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

3

2. Health

2.1 Basic Checks

BNGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BNGO has less shares outstanding
Compared to 5 years ago, BNGO has less shares outstanding
The debt/assets ratio for BNGO is higher compared to a year ago.
BNGO Yearly Shares OutstandingBNGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
BNGO Yearly Total Debt VS Total AssetsBNGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -13.88, we must say that BNGO is in the distress zone and has some risk of bankruptcy.
BNGO has a worse Altman-Z score (-13.88) than 94.44% of its industry peers.
BNGO has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.07, BNGO is doing good in the industry, outperforming 62.96% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -13.88
ROIC/WACCN/A
WACC46.94%
BNGO Yearly LT Debt VS Equity VS FCFBNGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

BNGO has a Current Ratio of 1.70. This is a normal value and indicates that BNGO is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.70, BNGO is not doing good in the industry: 64.81% of the companies in the same industry are doing better.
A Quick Ratio of 1.34 indicates that BNGO should not have too much problems paying its short term obligations.
The Quick ratio of BNGO (1.34) is worse than 68.52% of its industry peers.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.34
BNGO Yearly Current Assets VS Current LiabilitesBNGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

BNGO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.53%, which is quite impressive.
The Revenue for BNGO has decreased by -14.79% in the past year. This is quite bad
Measured over the past years, BNGO shows a very strong growth in Revenue. The Revenue has been growing by 24.89% on average per year.
EPS 1Y (TTM)66.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.92%
Revenue 1Y (TTM)-14.79%
Revenue growth 3Y19.62%
Revenue growth 5Y24.89%
Sales Q2Q%-13.36%

3.2 Future

Based on estimates for the next years, BNGO will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.92% on average per year.
The Revenue is expected to grow by 22.69% on average over the next years. This is a very strong growth
EPS Next Y91.12%
EPS Next 2Y39.66%
EPS Next 3Y25.68%
EPS Next 5Y14.92%
Revenue Next Year-0.27%
Revenue Next 2Y9.77%
Revenue Next 3Y21.7%
Revenue Next 5Y22.69%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BNGO Yearly Revenue VS EstimatesBNGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
BNGO Yearly EPS VS EstimatesBNGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BNGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BNGO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNGO Price Earnings VS Forward Price EarningsBNGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNGO Per share dataBNGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20 -30 -40

4.3 Compensation for Growth

BNGO's earnings are expected to grow with 25.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.66%
EPS Next 3Y25.68%

More info and screens

0

5. Dividend

5.1 Amount

BNGO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONANO GENOMICS INC

NASDAQ:BNGO (8/22/2025, 8:00:02 PM)

After market: 4.02 +0.02 (+0.5%)

4

-0.13 (-3.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners10.32%
Inst Owner Change-25.67%
Ins Owners0.05%
Ins Owner Change0%
Market Cap18.72M
Analysts78
Price Target7.82 (95.5%)
Short Float %7.11%
Short Ratio3.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-47.99%
Min EPS beat(2)-158.66%
Max EPS beat(2)62.68%
EPS beat(4)2
Avg EPS beat(4)-33.62%
Min EPS beat(4)-158.66%
Max EPS beat(4)62.68%
EPS beat(8)4
Avg EPS beat(8)-9.6%
EPS beat(12)5
Avg EPS beat(12)-9.29%
EPS beat(16)5
Avg EPS beat(16)-14.65%
Revenue beat(2)2
Avg Revenue beat(2)15.32%
Min Revenue beat(2)1.56%
Max Revenue beat(2)29.08%
Revenue beat(4)3
Avg Revenue beat(4)6.93%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)29.08%
Revenue beat(8)6
Avg Revenue beat(8)3.9%
Revenue beat(12)9
Avg Revenue beat(12)3.25%
Revenue beat(16)12
Avg Revenue beat(16)3.99%
PT rev (1m)4.55%
PT rev (3m)9.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.7%
EPS NY rev (1m)-0.55%
EPS NY rev (3m)12.05%
Revenue NQ rev (1m)-2.38%
Revenue NQ rev (3m)-3.42%
Revenue NY rev (1m)-4.52%
Revenue NY rev (3m)-5.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.66
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 0.47
EV/EBITDA N/A
EPS(TTM)-42.97
EYN/A
EPS(NY)-4.15
Fwd EYN/A
FCF(TTM)-9.32
FCFYN/A
OCF(TTM)-9.31
OCFYN/A
SpS6.08
BVpS10.3
TBVpS8.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -106.74%
ROE -173.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.74%
FCFM N/A
ROA(3y)-99.22%
ROA(5y)-76.96%
ROE(3y)-203.87%
ROE(5y)-150.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-61.43%
GM growth 5Y-48.22%
F-Score4
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.56%
Cap/Sales 0.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.7
Quick Ratio 1.34
Altman-Z -13.88
F-Score4
WACC46.94%
ROIC/WACCN/A
Cap/Depr(3y)12.46%
Cap/Depr(5y)12.34%
Cap/Sales(3y)4.56%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.92%
EPS Next Y91.12%
EPS Next 2Y39.66%
EPS Next 3Y25.68%
EPS Next 5Y14.92%
Revenue 1Y (TTM)-14.79%
Revenue growth 3Y19.62%
Revenue growth 5Y24.89%
Sales Q2Q%-13.36%
Revenue Next Year-0.27%
Revenue Next 2Y9.77%
Revenue Next 3Y21.7%
Revenue Next 5Y22.69%
EBIT growth 1Y53.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year86.93%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.08%
OCF growth 3YN/A
OCF growth 5YN/A